You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 25, 2025

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed University of Washington Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Australian and New Zealand Intensive Care Society Clinical Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Critical Care Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Institutes of Health Research (CIHR) Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container

Condition Name

Condition Name for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Healthy 4
Thrombosis 4
Covid19 4
Myocardial Infarction 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Thrombosis 13
Venous Thrombosis 7
Acute Kidney Injury 6
COVID-19 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container

Trials by Country

Trials by Country for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Location Trials
United States 44
China 16
Canada 14
Brazil 12
Germany 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Location Trials
California 7
New York 5
Texas 4
Ohio 3
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Phase 4 27
Phase 3 15
Phase 2/Phase 3 6
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Completed 47
Unknown status 13
Withdrawn 10
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container

Sponsor Name

Sponsor Name for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Ain Shams University 5
Azidus Brasil 4
GlaxoSmithKline 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Heparin Sodium 1,000 Units And Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Other 143
Industry 35
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Heparin Sodium: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction to Heparin Sodium

Heparin sodium, a naturally occurring anticoagulant, has been a cornerstone in medical treatment for over 80 years, particularly in managing conditions such as heart attacks, strokes, and blood clots. Its versatility and efficacy have led to its exploration in various clinical contexts, including the treatment of COVID-19.

Historical Use and Mechanism of Action

Heparin sodium works by activating antithrombin III, a protein that inhibits the coagulation cascade, thereby preventing the formation of blood clots[4].

Therapeutic Areas

  • Cardiovascular Diseases: Heparin is widely used to prevent and treat thrombosis in patients undergoing heart surgery, those with deep vein thrombosis, and those at risk of pulmonary embolism[5].
  • COVID-19: Recent studies suggest heparin may bind to the COVID-19 virus, potentially reducing its ability to enter cells and multiply[1].

Current Clinical Trials

Intranasal Heparin Trial (INHERIT)

The INHERIT trial is an ongoing study assessing the efficacy and safety of intranasal heparin for the treatment of early COVID-19 infection and the prevention of its spread within household contacts. This trial also investigates the effect of heparin on "long COVID" symptoms that persist more than 12 weeks after the initial infection[1].

Pharmacodynamic Profile Study

A phase I study is underway to evaluate the pharmacodynamic profile of sodium heparin of porcine origin in intravenous administration. This study aims to build on existing pharmacokinetic data and assess the toxicity of the product in healthy male participants[2].

Efficacy and Safety in Heart Surgery

A randomized, single-blind, multicentre study is verifying the effectiveness of heparin sodium in patients undergoing heart surgery who require cardiopulmonary bypass. The study focuses on controlling hemostasis during and after surgery[5].

Market Analysis

Product Launches and Innovations

B. Braun Medical Inc. has recently launched a new formulation of Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), expanding their portfolio of heparin premixed bags. This product is designed to maintain catheter patency and is manufactured using EXCEL® IV Containers, prioritizing patient and environmental safety[3].

Global Availability and Economic Impact

Heparin sodium is widely available and has been in use for over half a century. Its stability at room temperature, safety profile, and low cost make it an attractive option for global health initiatives, particularly in resource-limited settings[1].

Safety and Contraindications

Important Safety Information

Heparin sodium has several contraindications, including:

  • Uncontrollable active bleeding
  • History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT)
  • Severe thrombocytopenia
  • Known hypersensitivity to heparin or pork products[3].

Market Projections

Growing Demand in Healthcare

The demand for heparin sodium is expected to grow due to its expanding therapeutic applications, including its potential role in managing COVID-19. The global anticoagulant market is projected to increase, driven by the rising incidence of cardiovascular diseases and the need for effective anticoagulants.

Innovations and Future Directions

As research continues to uncover new uses for heparin sodium, such as its intranasal application for COVID-19, the market is likely to see further innovations. Companies like B. Braun are committed to improving the security of supply and manufacturing pharmaceuticals locally, which will enhance the availability and reliability of heparin products[3].

Expert Insights

Quotes from Industry Experts

"Heparin may be able to treat people with early COVID-19 infections and prevent infection amongst their close household contacts, helping to reduce the spread of the virus," notes a researcher involved in the INHERIT trial[1].

Illustrative Statistics

  • Heparin has been used for over 80 years, with its first approval in the US dating back to May 19, 1944[4].
  • The B. Braun Group of Companies employs over 64,000 people globally, highlighting the scale of operations and commitment to healthcare solutions[3].

Real-World Applications

Case Studies

In the context of COVID-19, the potential of heparin to bind to the virus and reduce its entry into cells could be a game-changer. For instance, if the INHERIT trial proves successful, it could offer a simple, inexpensive, and widely available treatment option for early COVID-19 infection[1].

Patient Safety

The use of heparin sodium in maintaining catheter patency is a common practice. For example, B. Braun's new formulation is designed to ensure catheter patency, reducing the risk of complications associated with catheter occlusion[3].

Regulatory Considerations

Compliance with Guidelines

Clinical trials involving heparin sodium must comply with regulatory guidelines. For instance, the phase I study on pharmacodynamic profile follows the guidelines of the ANVISA (National Health Surveillance Agency) Heparin Development Guide[2].

Future Research Directions

Expanding Therapeutic Uses

Research is ongoing to explore the therapeutic potential of heparin sodium beyond its current indications. The intranasal application for COVID-19 is a prime example of this expansion[1].

Addressing Global Health Needs

Given its safety profile, stability, and low cost, heparin sodium is poised to play a significant role in global health initiatives, particularly in regions with limited resources.

Key Takeaways

  • Versatile Anticoagulant: Heparin sodium has a broad range of therapeutic applications, including cardiovascular diseases and potential use in COVID-19 treatment.
  • Ongoing Clinical Trials: Studies like the INHERIT trial are exploring new uses for heparin sodium, such as intranasal administration for COVID-19.
  • Market Innovations: Companies are launching new formulations and products, enhancing the availability and safety of heparin sodium.
  • Global Impact: Heparin sodium's stability, safety, and low cost make it a valuable asset in global health initiatives.
  • Future Directions: Research is focused on expanding the therapeutic uses of heparin sodium and addressing global health needs.

FAQs

Q: What is heparin sodium used for?

A: Heparin sodium is used as an anticoagulant to prevent and treat blood clots, and it is being explored for its potential in treating COVID-19.

Q: What are the contraindications for heparin sodium?

A: Contraindications include uncontrollable active bleeding, history of heparin-induced thrombocytopenia, severe thrombocytopenia, and known hypersensitivity to heparin or pork products.

Q: Is heparin sodium safe for use in COVID-19 patients?

A: The safety and efficacy of heparin sodium for COVID-19 are being studied in clinical trials like the INHERIT trial.

Q: How is heparin sodium administered?

A: Heparin sodium can be administered intravenously, and there are also studies on intranasal administration for COVID-19.

Q: What companies are involved in the production and innovation of heparin sodium products?

A: Companies like B. Braun Medical Inc. are actively involved in producing and innovating heparin sodium products, including new formulations and manufacturing processes.

Sources

  1. Intranasal Heparin Trial (INHERIT) - Murdoch Children's Research Institute.
  2. Study With Heparin Sodium in Intravenous Administration - Veeva Systems.
  3. B. Braun Launches Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection - PR Newswire.
  4. Heparin Sodium - Drug Targets, Indications, Patents - Synapse.
  5. Efficacy and Safety of Sodium Heparin in Patients (Cristália) - Network of Care.
Last updated: 2025-01-16

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.